Search results
338 results found
A new roadmap for personalised preventionResearchAs co-leaders of work package 2 of the PROPHET project, we have recently completed a scoping review to establish identified biomarkers suitable for the use in the prevention of common diseases.
Circulating tumour DNA for cancer managementResearchAn in-depth examination of the prospects for using citizen generated data for health, and specifically to support predictive prevention of disease and to keep people healthier, longer
Personalised medicine and the UK insurance sectorCase studyAs part of the partnership between the University of Cambridge and Aviva, we were asked to produce a report examining the changing obligations on the UK insurance sector as personalised medicine becomes available.
Innovative ‘omics technologies for personalised medicineCase studyThe AHSN Network commissioned PHG Foundation to undertake an evidence review of genomics and genomic technologies likely to impact the delivery of personalised medicine in the NHS in the next two to three years.
Genomic surveillance in the roll out of vaccinesBlogViral genome sequencing will be vital during vaccine roll out to ensure they are still effective in the face of ongoing genetic changes to the virus.
A vision for the future of clinical researchBlogDr Philippa Brice dissects new UK government guidance on plans for the future of clinical research across the country.
International lessons for personalised medicineBlogThe benefits of personalised medicine are increasingly recognised around the world, enabled by advances in our ability to obtain and analyse information from genomic and other biomarkers and combine this with other medical information.
Where next for ctDNA liquid biopsy in the NHS?BlogCirculating tumour DNA (ctDNA) testing, also known as liquid biopsy, hit the headlines in 2020 with the announcement that GRAIL’s Galleri test – a test that aims to detect cancer early – will be trialled in the NHS.
Personalising therapy for age-related macular degenerationBlogGene therapy holds new hope for patients with age-related macular degeneration. If successful they will be beneficial to patients for whom no current therapies are available or do not work.